ROADS CLINICAL STUDY for PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS | REFER A PATIENT

ROADS Clinical Study
for patients with newly diagnosed metastatic brain tumors

Have you, or someone you know, been newly diagnosed with a metastatic brain tumor?

If so, you should be aware of the opportunity to participate in the ROADS Clinical Study.

This important clinical study compares 2 FDA-cleared radiation treatments that are proven safe and effective: GammaTile® Surgically Targeted Radiation Therapy (STaRT) and stereotactic radiotherapy (SRT).

The ROADS Clinical Study is enrolling now at participating hospitals across the country.

Do you quality for the study?

For more information contact a participating hospitals or take the ROADS Patient Evaluation.

Learn more about the ROADS clinical study

Overview

Metastatic brain tumors (also called secondary brain tumors) are caused by cancer cells that have metastasized or spread to the brain from a different part of the body.

Radiation therapy kills cancer cells and shrinks tumors. It is often combined with surgery and chemotherapy to help eliminate any remaining tumor cells and prevent the tumor from returning.1-3

The ROADS Clinical Study will provide more information about how effective GammaTile and SRT are at preventing brain tumor recurrence.

About the study

Study participants will be randomly divided into 2 treatment groups:

 

Following brain tumor removal surgery, clinical study participants will receive either GammaTile or SRT to the area where the tumor was.

Study participants in both groups may have additional brain tumors that may not be suitable for surgical removal. These remaining brain tumors will be treated with SRT.